Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: A meta-analysis

Liver International

Volumn 32, Issue 2, 2012, Pages 231-240

  Shi, Yu ^a   Wu, Yi Hua ^a,b   Wu, Wei ^a   Zhang, Wan Jun ^c   Yang, Jun ^a   Chen, Zhi ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; Non B and Non C chronic liver disease; Occult HBV infection

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS C ANTIBODY;

AGE; ARTICLE; CANCER RISK; DISEASE ASSOCIATION; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; POLYMERASE CHAIN REACTION; PREVALENCE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; VIRUS IDENTIFICATION;

CARCINOMA, HEPATOCELLULAR; COMORBIDITY; DATABASES, BIBLIOGRAPHIC; FEMALE; HEPACIVIRUS; HEPATITIS B ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84855552970     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02481.x     Document Type: Article

References (35)

1. Candotti D, Allain JP. Transfusion-transmitted hepatitis B virus infection. J Hepatol 2009; 51: 798-809.
2. Tabor E, Gerety RJ. Non-A, non-B hepatitis: new findings and prospects for prevention. Transfusion 1979; 19: 669-74.
3. Chemin I, Trepo C. Clinical impact of occult HBV infections. J Clin Virol 2005; 34(Suppl. 1): S15-21.
4. Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-6.
5. Niigaki M, Fukuda R, Hamamoto S, et al. Role of hepatitis B virus in non-B, non-C chronic liver disease: in vitro proliferation and interferon-gamma production of peripheral blood mononuclear cells in response to hepatitis B core antigen and its relation to hepatitis activity. Am J Gastroenterol 2000; 95: 239-47.
6. Higashi Y, Tada S, Miyase S, et al. Correlation of clinical characteristics with detection of hepatitis B virus X gene in liver tissue in HBsAg-negative, and HCV-negative hepatocellular carcinoma patients. Liver 2002; 22: 374-9.
7. Fwu CW, Chien YC, Kirk GD, et al. Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study. J Natl Cancer Inst 2009; 101: 1019-27.
8. Gujar SA, Michalak TI. Primary occult hepadnavirus infection induces virus-specific T-cell and aberrant cytokine responses in the absence of antiviral antibody reactivity in the Woodchuck model of hepatitis B virus infection. J Virol 2009; 83: 3861-76.
9. Hasegawa I, Orito E, Tanaka Y, et al. Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C. Liver Int 2005; 25: 247-53.
10. Ikeda K, Kobayashi M, Someya T, et al. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J Viral Hepat 2009; 16: 437-43.
11. Miura Y, Shibuya A, Adachi S, et al. Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails. Hepatol Res 2008; 38: 546-56.
12. Obika M, Shinji T, Fujioka S, et al. Hepatitis B virus DNA in liver tissue and risk for hepatocarcinogenesis in patients with hepatitis C virus-related chronic liver disease. A prospective study. Intervirology 2008; 51: 59-68.
13. Shetty K, Hussain M, Nei L, Reddy KR, Lok AS. Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl 2008; 14: 534-40.
14. Squadrito G, Pollicino T, Cacciola I, et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 2006; 106: 1326-30.
15. Matsuoka S, Nirei K, Tamura A, et al. Influence of occult hepatitis B virus coinfection on the incidence of fibrosis and hepatocellular carcinoma in chronic hepatitis C. Intervirology 2008; 51: 352-61.
16. Adachi S, Shibuya A, Miura Y, et al. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus. Scand J Gastroenterol 2008; 43: 849-56.
17. Falasca K, Ucciferri C, Dalessandro M, et al. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann Clin Lab Sci 2006; 36: 144-50.
18. Walter SD. Variation in baseline risk as an explanation of heterogeneity in meta-analysis. Stat Med 1997; 16: 2883-900.
19. Corvol JC, Bouzamondo A, Sirol M, et al. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Intern Med 2003; 163: 669-76.
20. Kao JH, Chen PJ, Lai MY, Chen DS. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002; 40: 4068-71.
21. Fang Y, Shang QL, Liu JY, et al. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect 2009; 58: 383-8.
22. Chen CH, Changchien CS, Lee CM, et al. A study on sequence variations in pre-S/surface, X and enhancer II/core promoter/precore regions of occult hepatitis B virus in non-B, non-C hepatocellular carcinoma patients in Taiwan. Int J Cancer 2009; 125: 621-9.
23. Tanaka T, Inoue K, Hayashi Y, et al. Virological significance of low-level hepatitis B virus infection in patients with hepatitis C virus associated liver disease. J Med Virol 2004; 72: 223-9.
24. Yotsuyanagi H, Shintani Y, Moriya K, et al. Virologic analysis of non-B, non-C hepatocellular carcinoma in Japan: frequent involvement of hepatitis B virus. J Infect Dis 2000; 181: 1920-8.
25. Pollicino T, Squadrito G, Cerenzia G, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126: 102-10.
26. Alencar RS, Gomes MM, Sitnik R, et al. Low occurrence of occult hepatitis B virus infection and high frequency of hepatitis C virus genotype 3 in hepatocellular carcinoma in Brazil. Braz J Med Biol Res 2008; 41: 235-40.
27. Branco F, Mattos AA, Coral GP, et al. Occult hepatitis B virus infection in patients with chronic liver disease due to hepatitis C virus and hepatocellular carcinoma in Brazil. Arq Gastroenterol 2007; 44: 58-63.
28. Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis 2009; 27: 80-92.
29. Allain JP. Occult hepatitis B virus infection and transfusion. J Hepatol 2006; 44: 617; author reply 8-9.
30. Okada S, Sato T, Okusaka T, et al. Past exposure to hepatitis B virus as a risk factor for hepatocellular carcinoma in patients with chronic liver disease. Br J Cancer 1998; 77: 2028-31.
31. Tennant BC, Toshkov IA, Peek SF, et al. Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology 2004; 127(Suppl. 1): S283-93.
32. Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett 2009; 286: 52-9.
33. Hoofnagle JH, Di Bisceglie AM. Serologic diagnosis of acute and chronic viral hepatitis. Semin Liver Dis 1991; 11: 73-83.
34. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-8.
35. Grob P, Jilg W, Bornhak H, et al. Serological pattern "anti-HBc alone": report on a workshop. J Med Virol 2000; 62: 450-5.